Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study
Related Posts
Williams SL, Benedict K, Jackson BR, Rajeev M, Cooksey G, Ruberto I, Williamson T, Sunenshine RH, Osborn B, Oltean HN, Reik RR, Freedman MS, Spec[...]
Phiri K, Hagstrom C, Lungu E, Balakasi K, Songo J, Makwaya A, Smith D, Worku A, Hoffman R, Phiri S, Dovel K, van Oosterhout JJ.[...]
Ehrenberg PK, Geretz A, Volcic M, Izumi T, Yum LK, Waickman A, Shangguan S, Paquin-Proulx D, Creegan M, Bose M, Machmach K, McGraw A, Narahari[...]